{"id":"W2033816200","doi":"10.1016/s1470-2045(14)71135-0","title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":544,"is_retracted":false,"has_abstract":false,"ca_institutions":"Juravinski Cancer Centre; Université Laval; Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Carboplatin; Tolerability; Internal medicine; Regimen; Ovarian cancer; Chemotherapy; Oncology; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Phases of clinical research; Urology; Cancer; Randomized controlled trial; Cisplatin; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001807734,0.002229034,0.003580784,0.0004732449,0.000429828,0.001552536,0.0009897881,0.002067053,0.009320953],"category_scores_gemma":[0.00259443,0.0009755517,0.002573171,0.0006235606,0.001681433,0.001620607,0.0007974948,0.004317354,0.00137701],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001062983,"about_ca_system_score_gemma":0.001139053,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001075262,"about_ca_topic_score_gemma":0.002102761,"domain_scores_codex":[0.9991542,0.0004834522,0.00004517959,0.0001528572,0.0000436585,0.0001206292],"domain_scores_gemma":[0.9988759,0.0004014331,0.0002204019,0.0001128063,0.00004053906,0.0003489516],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9809524,0.002125431,0.000384229,0.0007354862,0.001010368,0.00004517558,0.00004989701,0.0004041727,0.0009703272,0.00009539831,0.0008562115,0.01237085],"study_design_scores_gemma":[0.9768296,0.02117477,0.0005764387,0.0000328423,0.0003847621,0.00003119622,0.00001687193,0.0001563369,0.00009491893,0.0001540914,0.0005377709,0.00001045833],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.968951,0.0136287,0.001320668,0.002646122,0.001694432,0.005184971,0.002715407,0.000235226,0.00362349],"genre_scores_gemma":[0.9733208,0.007589741,0.002059875,0.002741515,0.0007644061,0.00547319,0.00235141,0.00006268117,0.005636385],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009320953,"threshold_uncertainty_score":0.03118169,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05582660886094198,"score_gpt":0.3904644590514653,"score_spread":0.3346378501905233,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}